Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

被引：0

作者：

N. I. Bouwer

T. G. Steenbruggen

J. van Rosmalen

H. N. Rier

J. J. E. M. Kitzen

M. L. van Bekkum

A. J. Ten Tije

P. C. de Jong

J. C. Drooger

C. Holterhues

C. H. Smorenburg

M. J. M. Kofflard

E. Boersma

G. S. Sonke

M.-D. Levin

A. Jager

机构：

[1] Albert Schweitzer Hospital,Department of Internal Medicine

[2] Albert Schweitzer Hospital,Department of Cardiology

[3] The Netherlands Cancer Institute,Department of Medical Oncology

[4] Erasmus MC,Department of Biostatistics

[5] University Medical Centre Rotterdam,Department of Medical Oncology

[6] Erasmus MC,Department of Medical Oncology

[7] Cancer Institute,Department of Medical Oncology

[8] Reinier de Graaf Hospital,Department of Medical Oncology

[9] Amphia Hospital,Department of Medical Oncology

[10] Sint Antonius Hospital,Department of Medical Oncology

[11] Ikazia Hospital,Department of Cardiology

[12] Haga Hospital,undefined

[13] Erasmus MC,undefined

[14] University Medical Centre Rotterdam,undefined

来源：

Breast Cancer Research and Treatment | 2021年 / 186卷

关键词：

HER2-positive metastatic breast cancer; Trastuzumab treatment; Cardiotoxicity; LVEF monitoring; Screening for cardiotoxicity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：851 / 862

页数：11

共 50 条

[31] Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab
Kaplan, Muhammet Ali
Ertugrul, Hamza
Firat, Ugur
Kucukoner, Mehmet
Inal, Ali
Urakci, Zuhat
Pekkolay, Zafer
Isikdogan, Abdurrahman
BREAST CANCER, 2015, 22 (05) : 503 - 509
[32] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
Andrew D. Seidman
Larry Norton
Current Oncology Reports, 2005, 7 (1) : 9 - 11
[33] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, Sandra M.
Baselga, Jose
Kim, Sung-Bae
Ro, Jungsil
Semiglazov, Vladimir
Campone, Mario
Ciruelos, Eva
Ferrero, Jean-Marc
Schneeweiss, Andreas
Heeson, Sarah
Clark, Emma
Ross, Graham
Benyunes, Mark C.
Cortes, Javier
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
[34] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
Perez, Jose
Garrigos, Laia
Gion, Maria
Janne, Pasi A.
Shitara, Kohei
Siena, Salvatore
Cortes, Javier
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
[35] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
Milani, Andrea
Montemurro, Filippo
Gioeni, Luisa
Aglietta, Massimo
Valabrega, Giorgio
BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
[36] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Murthy, R. K.
Loi, S.
Okines, A.
Paplomata, E.
Hamilton, E.
Hurvitz, S. A.
Lin, N. U.
Borges, V.
Abramson, V.
Anders, C.
Bedard, P. L.
Oliveira, M.
Jakobsen, E.
Bachelot, T.
Shachar, S. S.
Mueller, V.
Braga, S.
Duhoux, F. P.
Greil, R.
Cameron, D.
Carey, L. A.
Curigliano, G.
Gelmon, K.
Hortobagyi, G.
Krop, I.
Loibl, S.
Pegram, M.
Slamon, D.
Palanca-Wessels, M. C.
Walker, L.
Feng, W.
Winer, E. P.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
[37] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
Haddley, K.
DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
[38] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
[39] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
Al-Naqqash, Manwar
Jasim Al-Serarati, Waleed
Farooq Kareem, Tara
BREAST JOURNAL, 2021, 27 (03): : 297 - 299
[40] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
Haq, R.
Gulasingam, P.
CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95

← 1 2 3 4 5 →